Background
==========

Cholangiocarcinoma (CCA) is the second most common hepatic malignant tumor, and its incidence has been increasing globally \[[@b1-medscimonit-26-e921162],[@b2-medscimonit-26-e921162]\]. Most patients are in advanced stage. Treatments for patients who have unresectable or advanced CCA are limited. Various chemotherapeutic drugs have been used for treating CCA patients, like 5-fluorouracil, gemcitabine (GEM), cisplatin (CIS), and doxorubicin (DOX) \[[@b3-medscimonit-26-e921162]\], but CCA responds poorly to these drugs \[[@b4-medscimonit-26-e921162]\]. The current median overall survival after standard chemotherapy regimens is less than 1 year \[[@b5-medscimonit-26-e921162]\]. Therefore, it is necessary to develop alternative treatment approaches for CCA.

Humans have used herbs for treating disease for at least 60 000 years \[[@b6-medscimonit-26-e921162]\], showing they have a wide range of pharmacological properties, including anticancer activity \[[@b7-medscimonit-26-e921162]--[@b9-medscimonit-26-e921162]\]. Herbal formulae can act on many targets through their various components and play an integral role in key biological processes to exert therapeutic roles during disease development \[[@b10-medscimonit-26-e921162]\]. RA is a traditional Chinese medicine which was listed as being in the top grade in *Shennong' Materia Medica* \[[@b11-medscimonit-26-e921162]\]. Several studies have shown that RA has antitumor activity \[[@b12-medscimonit-26-e921162]\]. RA extracts can inhibit the growth of lung adenocarcinoma cells \[[@b13-medscimonit-26-e921162]\]. Zhang et al. found that concentration-dependent antitumor activity was confirmed in laryngeal carcinoma SCC15 cell line treated with total RA glucosides \[[@b14-medscimonit-26-e921162]\], and RA can effectively promote oral cancer Hep-2 cell line apoptosis \[[@b15-medscimonit-26-e921162]\]. In addition, RA has immune-modulating activities \[[@b16-medscimonit-26-e921162]\]. It was reported that RA can inhibit the phagocytic activity of peritoneal macrophages, promote the transformation of spleen lymphocytes \[[@b17-medscimonit-26-e921162]\], secrete interleukin (IL)-2, and affect the activity of natural killer (NK) cells \[[@b17-medscimonit-26-e921162]--[@b19-medscimonit-26-e921162]\]. However, there is no published study that analyzed the effect of RA in treating CCA. Therefore, we performed the present study to assess the effect of RA on CCA and to identify its biological target and molecular mechanism to provide a scientific reference for further research.

Network pharmacology is an emerging and novel approach for exploring the systemic mechanisms of therapeutic compounds in disease \[[@b20-medscimonit-26-e921162],[@b21-medscimonit-26-e921162]\]. The use of network pharmacology to identify herbal targets and potential mechanisms is becoming important to save money, effort, and time needed for drug discovery and design \[[@b22-medscimonit-26-e921162],[@b23-medscimonit-26-e921162]\]. Network pharmacology has successfully realized the construction and visualization of drug--disease--target networks, which is helpful to evaluate the mechanism of drugs from multiple perspectives \[[@b24-medscimonit-26-e921162],[@b25-medscimonit-26-e921162]\]. Network pharmacology can be applied in identifying the pharmacological targets and mechanisms of RA in CCA.

Therefore, we investigated the antitumor activity of RA on CCA in an *in vitro* study. We then used network pharmacology to analysis the core targets and biological functions, pathways, and mechanisms of RA in treating CCA. We verified the core targets and pathway by Western blotting. A schematic flowchart of the experiment design is shown in [Figure 1](#f1-medscimonit-26-e921162){ref-type="fig"}.

Material and Methods
====================

Preparation of freeze-dried RA water extract
--------------------------------------------

Radix Astragali (root pieces, origin: Inner Mongolia, China) was purchased from Weifang Hospital of Traditional Chinese Medicine. We prepared aqueous extracts of freeze-dried RA. A total of 15 g of freeze-dried RA pieces was boiled in 500 mL water for 30min. The water extract solution was concentrated to a volume of 250mL. Finally, the extract solution was filtrated with a 0.22-μm filter to remove bacteria and then was maintained at 4°C until use.

Cell lines and cell culture
---------------------------

The CCA cell line QBC939 cells were purchased from the Shanghai Cell Bank of the Chinese Science Academy (Shanghai, China). Cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum in a cell culture incubator (Thermo Fisher Scientific, Waltham, MA, USA) at 37°C and 5% CO~2~.

Cell viability assay
--------------------

QBC939 cells (5×10^3^ cells/well) were plated into 96-well plates and treated with various concentrations of RA (0, 100, 200, and 400 μg/mL), and PBS was used in the control group. After 24 h, cell viability was assessed by CCK8 assay. We cultured the cells for 1 h with CCK8 agent, then the optical density (OD) was measured at 450 nm on an enzyme-labeling instrument. Additionally, QBC939 cells were seeded into 6-well plates and cultured until the cell density reached 50%. After treatment with various concentrations of RA (0, 100, 200, and 400 μg/mL), the cells were imaged using an IncuCyte^®^ S3 Live-Cell Analysis System (Essen BioScience) every 1 h, and 9 fields of view were imaged per well.

Trypan blue staining
--------------------

After being treated with various concentrations of RA (0, 100, 200, and 400 μg/mL), QBC939 cells were digested and 50-μL of cell suspension was mixed with 50 μL trypan blue staining solution. The mixture was placed into a hematocytometer and counted under a microscope within 10 min.

Collection chemical components and targets for RA
-------------------------------------------------

To evaluate the pharmacokinetics properties of RA, we used the TCMSP database (*<http://lsp.nwu.edu.cn/>*) \[[@b26-medscimonit-26-e921162]\] to collect information on chemical components for RA, which is a systems pharmacology resource used to evaluate traditional Chinese medicines or related compounds. With the pharmacokinetic information retrieval filter based on the TCMSP platform, the oral bioavailability (OB) and drug-likeness (DL) were set to ≥30% and ≥0.18 to obtain qualified herbal compounds. The chemical structures of the compounds were drawn using ChemBioOffice 2010.

Collection of disease targets
-----------------------------

Potential genes associated with CCA were collected from GeneCards (*<https://www.genecards.org/>*) \[[@b27-medscimonit-26-e921162]\] with the keyword "cholangiocarcinoma" and Online Mendelian Inheritance in Man (OMIM) (*<https://www.omim.org/>*) \[[@b28-medscimonit-26-e921162]\] with the keyword "bile duct carcinoma".

Construction of components--targets--disease network
----------------------------------------------------

Venny2.1.0 (*<http://bioinfogp.cnb.csic.es/tools/venny/>*) \[[@b29-medscimonit-26-e921162]\] was used to screen for common RA targets and CCA-related targets. Cytoscape-v3.7.1 \[[@b30-medscimonit-26-e921162]\] software was used to create the model of the target--disease and component--target network, and the Merge function was used to construct the component--target--disease network model. Results were further analyzed to determine the mutual relationships in the network model.

Protein--protein interaction (PPI) data
---------------------------------------

The Search Tool for the Retrieval of Interacting Genes (STRING) database (*<https://string-db.org/>*, ver.10.5) \[[@b31-medscimonit-26-e921162]\] was used to analyze protein--protein interactions of the common targets from the RA targets and CCA-related targets. The database defines PPIs with confidence ranges for data scores; in the present study, PPIs with medium confidence (0.4) were further examined.

Gene function and pathway enrichment analysis
---------------------------------------------

clusterProfiler \[[@b32-medscimonit-26-e921162]\] is an R package for comparing biological themes among gene clusters, which can be used to analyze functional and pathway enrichment information on the gene of interest. The common targets were input into the R 3.6.0 platform by clusterProfiler software, using an enrichment analysis method with the Gene Ontology (GO) \[[@b33-medscimonit-26-e921162]\] and Kyoto Encyclopedia of Genes and Genomes (KEGG) \[[@b34-medscimonit-26-e921162]\] databases. Enriched GO terms were defined and relevant pathways with *p* values \<0.05 were selected. Target--pathway and constituent--pathway networks were built to show an overview of the interactions between RA targets and CCA \[[@b35-medscimonit-26-e921162]\].

Analysis of gene expression and tumor-infiltrating immune cells
---------------------------------------------------------------

Using the online tool TIMER (*<https://cistrome.shinyapps.io/timer/>*) \[[@b36-medscimonit-26-e921162]\], we investigated the correlation between the expression of core targets and tumor-infiltrating immune cells (B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells) in CCA, which is a comprehensive resource for systematic analysis of immune infiltrates across diverse cancer types \[[@b37-medscimonit-26-e921162]\].

Western blotting analysis
-------------------------

Total protein was extracted from QBC939 cells after RA treatment (0, 100, 200, and 400 μg/mL) and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by transfer of the proteins onto a polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA). The primary antibodies were: caspase3 (NO.9662; Cell Signaling Technology, Danvers, MA, USA), SAPK/JNK (NO.9252; Cell Signaling Technology), p-SAPK/JNK (NO.4668; Cell Signaling Technology), c-MYC (NO.9402; Cell Signaling Technology), EGFR (NO.4267; Cell Signaling Technology), p-EGFR (NO.3777; Cell Signaling Technology), and PARP (NO.9542; Cell Signaling Technology).

Statistical analysis
--------------------

Statistical analysis was performed using the SPSS program (version 23.0). All the data are presented as means±standard deviation. Differences were evaluated by Student's *t* test, with *p*\<0.05 considered statistically significant.

Results
=======

RA inhibits the cell proliferation of QBC939 cells
--------------------------------------------------

After incubating the cells with various concentrations of RA (0, 100, 200, and 400 μg/mL,) for 24 h, it was found that all tested concentrations of RA inhibited the proliferation of QBC939 cells with the CCK8 assay (*p*\<0.05). Compared with the control group, growth inhibition increased in a concentration-dependent manner (100, 200, 400 μg/mL) ([Figure 2A](#f2-medscimonit-26-e921162){ref-type="fig"}). The IncuCyte^®^ S3 Live-Cell Analysis System was used to image surviving cells, which clearly revealed the gradual decrease in the numbers of QBC939 cells with increasing concentration ([Figure 2B](#f2-medscimonit-26-e921162){ref-type="fig"}). RA also influenced the morphological characteristics and adherence of the cells to the plate; the cells displayed apoptotic morphology ([Supplementary Figure 1](#s1-medscimonit-26-e921162){ref-type="supplementary-material"}).

Trypan blue counting analysis
-----------------------------

Trypan blue staining is often applied to detect cell death. As shown in [Figure 3](#f3-medscimonit-26-e921162){ref-type="fig"}, the living cells are non-stained, while dead cells are dyed blue. After counting the dead cells and living cells, we calculated the cell viability. The results showed that compared with the control group, the cell viability significantly decreased in a concentration-dependent manner after treatment with RA (*p*\<0.05).

Screening results of components and target proteins
---------------------------------------------------

Using the TCMSP database, 20 herbal compounds were identified, 16 of which had corresponding targets. The 97 targets of the 16 compounds were obtained and the details are presented in [Table 1](#t1-medscimonit-26-e921162){ref-type="table"}. These 97 identified targets were further investigated.

Results of CCA targets
----------------------

We acquired 1452 known correlated targets from GeneCards, and 83 known related targets were acquired from OMIM. After redundant names were deleted, 1529 known CCA-related targets were collected, and the list of targeted genes is shown in [Supplementary Table 1](#s2-medscimonit-26-e921162){ref-type="supplementary-material"}.

Network construction
--------------------

Of the 1529 known cholangiocarcinoma-related targets, 50 targets are involved in RA, and through Venny 2.1.0, the common targets were obtained, including PGR, PTGS1, CHEK1, PRSS1, CHRM3, ESR1, PPARG, GSK3B, F7, BCL2, CASP3, MAPK8, CYP1A1, SELE, ALOX5, GSTP1, AHR, NR1I3, GSTM1, EGFR, VEGFA, CCND1, CASP9, PLAU, RB1, IL6, TP63, ELK1, CASP8, RAF1, PRKCA, HIF1A, ERBB2, MYC, PTGER3, BIRC5, NOS3, HSPB1, CCNB1, NFE2L2, NQO1, PARP1, CHEK2, HSF1, CRP, RASSF1, IRF1, ERBB3, PON1, and HK2, which all act on the pathway of treating cholangiocarcinoma by RA ([Figure 4A](#f4-medscimonit-26-e921162){ref-type="fig"}, [Table 2](#t2-medscimonit-26-e921162){ref-type="table"}).

The 50 green nodes represent the target of cholangiocarcinoma, and the 15 pink nodes represent the target protein of the RA compounds. Network construction of compound disease targets consists of 67 nodes and 172 edges. Among them, 65 nodes and 107 edges directly reflect the interaction between the RA targets and cholangiocarcinoma targets ([Figure 4B](#f4-medscimonit-26-e921162){ref-type="fig"}).

PPI network of common targets
-----------------------------

Protein--protein interactions (PPI) of the 50 disease-related targets were analyzed using the PPI network. After setting the interaction score to medium confidence and hiding disconnected nodes in the network, the PPI network contained 48 nodes and 361 edges ([Figure 5A](#f5-medscimonit-26-e921162){ref-type="fig"}), with a 14.4 average node degree and PPI enrichment *p* value\<1.0e-16, showing the multi-target characteristics of RA. According to the degree of nodes exported from the STRING database, the order of key targets was analyzed, and the top 30 nodes with a degree ≥10 were selected ([Figure 5B](#f5-medscimonit-26-e921162){ref-type="fig"}).

GO and KEGG pathway analysis
----------------------------

GO and KEGG analyses were performed to further study the biological process of the 50 common targets. As shown in [Figure 6A](#f6-medscimonit-26-e921162){ref-type="fig"}, the top 10 significantly enriched GO terms (adjusted *p* value \<0.001) were used and included the response to ubiquitin-like protein ligase binding, DNA-binding transcription activator activity, RNA polymerase II-specific, nuclear receptor activity, transcription factor activity, direct ligand regulated sequence-specific DNA binding, proximal promoter sequence-specific DNA binding, ubiquitin protein ligase binding, protein heterodimerization activity, RNA polymerase II proximal promoter sequence-specific DNA binding, Hsp90 protein binding, and E-box binding. The results were highly correlated with anticancer activities, demonstrating that RA exerted its effects against CCA by engaging in the above biological processes and cell functions.

Furthermore, these 50 genes participated in 79 KEGG pathways with adjusted *p* values \<0.01; after sorting the adjusted *p* values, the top 20 were analyzed ([Figure 6B](#f6-medscimonit-26-e921162){ref-type="fig"}).

Association of core targets' expression with CCA purity and immune infiltration
-------------------------------------------------------------------------------

The tumor microenvironment includes cancer cells, matrix cells, and infiltrating immune cells. Infiltrating immune cells are an independent predictor of sentinel lymph node status and survival of cancer patients \[[@b38-medscimonit-26-e921162],[@b39-medscimonit-26-e921162]\]. Tumor purity plays a role in analyzing immune infiltration in clinical tumor samples by genomics methods \[[@b40-medscimonit-26-e921162]\]. The expressions of caspase3 and MYC were significantly negatively correlated with tumor purity via TIMER platform, while EGFR and PARP were not associated with tumor purity. Interestingly, we found expression of caspase3 was positively correlated with infiltration level of B cells in CCA, and expression of MYC was positively correlated with the infiltration level of B cells, CD4+ cells, macrophages, neutrophils, and dendritic cells in CCA ([Figure 7A, 7B](#f7-medscimonit-26-e921162){ref-type="fig"}).

Changes in core target expression
---------------------------------

To verify the core targets in the network of RA and CCA, we investigated the expression of core target proteins by Western blotting in QBC939 cells treated with RA, and found that RA downregulated the P-EGFR/EGFR and p-MAPK8/MAPK8 ratios, upregulated the cleaved caspase3/caspase3 ratio, and reduced the expression of c-MYC and PARP ([Figure 8A, 8B](#f8-medscimonit-26-e921162){ref-type="fig"}). Western blotting results showed concentration-dependent antitumor activity in QBC939 cells treated with RA through these targets (*p*\<0.05).

Discussion
==========

Cholangiocarcinoma is a relatively common malignant tumor derived from the intrahepatic Due to difficulties in detection and drug resistance, it is very important to explore the regulation of CCA biological characteristics and find new treatment methods for multi-modal management of CCA.

Network pharmacology can improve drug efficacy and the success rate of clinical trials, as well as decrease in the costs of drug discovery via exploring the regulation of signaling pathways with multiple channels \[[@b42-medscimonit-26-e921162]\]. In our study, the network pharmacology findings from web-based databases revealed core gene targets, and we explored the biological functions, pathways, and mechanisms of RA in CCA. These findings support that RA is a promising resource with specific therapeutic effects on CCA.

RA is a type of astragalus, and several studies have shown that astragalus is associated with antitumor \[[@b12-medscimonit-26-e921162]\] and immune-modulating activities \[[@b16-medscimonit-26-e921162]\]. In network pharmacology analysis, the network of compound disease targets revealed quercetin and kaempferol as key active ingredients in RA responsible for the therapeutic effects against CCA. Several studies have suggested that quercetin is helpful for treating CCA as a dietary phytochemical with anti-inflammatory and antitumor effects \[[@b43-medscimonit-26-e921162],[@b44-medscimonit-26-e921162]\] and may be useful against CCA as a cancer chemopreventive drug. Kaempferol has antioxidant, anti-inflammatory, and antitumor activities \[[@b45-medscimonit-26-e921162]--[@b47-medscimonit-26-e921162]\]. Qin et al. \[[@b48-medscimonit-26-e921162]\] showed that kaempferol has potent effects against CCA both *in vitro* and *in vivo* via the PI3K/AKT pathway, which is involved in apoptosis, proliferation, and invasion. In our *in vitro* study, the RA extract was cytotoxic and inhibited the proliferation of the bile duct carcinoma cell line QBC939.

Important predictive biotargets for RA in CCA were identified as caspase3, MAPK8, MYC, EGFR, and PARP. Caspase3, a cysteine-aspartic acid protease, plays a central role in the execution phase of cell apoptosis. As an executioner caspase, the caspase3 zymogen has activity after it is cleaved by an initiator caspase when apoptotic signaling events have occurred \[[@b49-medscimonit-26-e921162]\]. Caspase3 plays a dominant role in the hallmark caspase cascade, which is characteristic of the apoptotic pathway triggered by extrinsic activation \[[@b50-medscimonit-26-e921162]\]. MAPK8, a transduction protein, controls several cellular processes, including cell proliferation and survival \[[@b51-medscimonit-26-e921162]\]. Nishikawa et al. reported that MAPK signaling appears to induce a biliary proliferation program in hepatocytes or liver bipotential cells, implicating this pathway in human CCA \[[@b52-medscimonit-26-e921162]\]. In human intrahepatic CCA, TNF is highly expressed near intrahepatic CCA lesions, and CCA p-JNK, and reactive oxygen species (ROS) accumulation in surrounding hepatocytes are present, causing cholangiocellular proliferation/differentiation and carcinogenesis. Targeting the ROS/TNF/JNK axis may improve intrahepatic CCA therapy \[[@b53-medscimonit-26-e921162]\].

C-MYC is the most well-known and studied member of the MYC oncoprotein family and it is estimated that in up to 70% of human cancers, c-MYC expression is elevated or deregulated through different mechanisms and is associated with an invasive cancer phenotype \[[@b54-medscimonit-26-e921162]\]. Many studies have demonstrated that c-MYC induction promotes cholestatic liver injury and CCA progression \[[@b55-medscimonit-26-e921162]\]. EGFR belongs to the HER/ErbB family of tyrosine kinase receptors. In many types of cancer, EGFR activation inhibits cell--cell adhesion by destabilizing the complex of E-cadherin/β-catenin, promotes tumor metastasis, and contributes to the procurement of a motile phenotype \[[@b56-medscimonit-26-e921162]--[@b58-medscimonit-26-e921162]\]. In CCA, overexpression of EGFR is related to tumor progression \[[@b59-medscimonit-26-e921162]--[@b64-medscimonit-26-e921162]\], and the EGF/EGFR axis contributes to epithelial-mesenchymal transition in CCA tumor cells, promoting the progression of this type of cancer \[[@b65-medscimonit-26-e921162]\]. PARP is a nuclear DNA-binding protein and is an important component involved in single-strand break damage repair \[[@b66-medscimonit-26-e921162]\]. Upon DNA damage, PARP-1 catalyzes the PARylation of acceptor proteins and repairs damaged DNA via base excision repair to maintain genomic stability \[[@b67-medscimonit-26-e921162]\]. PARP inhibitors can theoretically enhance tumor cell death, and combining PARP inhibitors such as olaparib with radiation may contribute to treatment of CCA \[[@b68-medscimonit-26-e921162]\].

To further explore the biological functions of the core targets, we used to TIMER database. The expression of caspase3 and MYC was negatively associated with tumor purity, which is correlated with diverse immune infiltration levels in CCA. Caspase3 expression levels are positively associated with the infiltration level of B cells in CCA, and the MYC expression level is positively associated with the infiltration level of B cells, CD4+ cells, macrophages, neutrophils, and dendritic cells in CCA. The results of TIMER suggest that the functions of core targets are related to immunological regulation of the tumor microenvironment. Immune infiltration is an emerging hallmark of cancer and plays an important role in tumor initiation and progression \[[@b69-medscimonit-26-e921162],[@b70-medscimonit-26-e921162]\]. The tumor microenvironment is a key determinant in distant metastasis and development, in which evolution of the tumor can be traced back to immune-escaping clones \[[@b71-medscimonit-26-e921162]\]. Based on the relationship between the core genes and immune infiltration, RA may inhibit tumor initiation and progression by regulating the tumor microenvironment.

The KEGG results showed that RA regulates the EGFR tyrosine kinase inhibitor resistance pathway as the pharmacological mechanisms of the therapeutic effect of RA against CCA. An EGFR inhibitor was the first targeted drug used for tumor therapy and has been approved for treating metastatic non-small-cell lung cancer, pancreatic cancer, colorectal cancer, and squamous cell carcinoma of the head and neck \[[@b72-medscimonit-26-e921162]\]. As EGFR expression is decreased, downstream signaling in malignant tumor cells is inhibited, leading to inhibition of metastasis, growth, proliferation, differentiation, and angiogenesis and increased cancer cell apoptosis \[[@b73-medscimonit-26-e921162]\]. However, nearly all tumors acquire EGFR tyrosine kinase inhibitor resistance after various periods of time \[[@b74-medscimonit-26-e921162]\].

In our study, the Western blotting results showed that RA downregulated the P-EGFR/EGFR and p-MAPK8/MAPK8 ratios, upregulated the cleaved caspase3/caspase3 ratio, and reduced the expression of c-MYC and PARP. These *in vitro* results support the network pharmacology data and demonstrate that RA affects protein expression of core genes and alters the EGFR tyrosine kinase inhibitor resistance pathway. RA inhibits CCA progression by promoting cell apoptosis and blocking cell proliferation/differentiation and carcinogenesis.

Conclusions
===========

RA appears to be an effective drug when used as adjuvant therapy. The core targets identified included caspase3, MAPK8, MYC, EGFR, and PARP in the network of RA and CCA, indicating potential as therapeutic biomolecules for treating CCA. Further studies are needed to demonstrate that RA is an active plant medicinal material useful for developing a safe and effective multi-targeted anticancer treatment for CCA.

Supplementary Data
==================

###### 

The cells were imaged using the IncuCyte^®^ S3 Live-Cell Analysis System. RA influenced the morphological characteristics and adherence of the cells to the plate.

###### 

Targets from OMIM.

  Gene/locus   Gene/locus name                                                                                 Gene/locus MIM number
  ------------ ----------------------------------------------------------------------------------------------- -----------------------
  BCC1         Basal cell carcinoma, susceptibility to, 1                                                      605462
  MYCL         Oncogene MYC, lung carcinoma-derived                                                            164850
  LMYC         Oncogene MYC, lung carcinoma-derived                                                            164850
  BCAS2        Breast carcinoma amplified sequence 2                                                           605783
  DAM1         Breast carcinoma amplified sequence 2                                                           605783
  PRN1         Papillary thyroid carcinoma with papillary renal neoplasia                                      605642
  PTCPRN       Papillary thyroid carcinoma with papillary renal neoplasia                                      605642
  RCCP1        Papillary renal cell carcinoma, translocation-associated                                        179755
  PRCC         Papillary renal cell carcinoma, translocation-associated                                        179755
  BCC2         Basal cell carcinoma, susceptibility to, 2                                                      613058
  NMTC3        Nonmedullary thyroid carcinoma 3                                                                606240
  ABCB11       ATP-binding cassette, subfamily B, member 11 (bile salt export pump)                            603201
  BSEP         ATP-binding cassette, subfamily B, member 11 (bile salt export pump)                            603201
  SPGP         ATP-binding cassette, subfamily B, member 11 (bile salt export pump)                            603201
  PFIC2        ATP-binding cassette, subfamily B, member 11 (bile salt export pump)                            603201
  BRIC2        ATP-binding cassette, subfamily B, member 11 (bile salt export pump)                            603201
  BG37         G protein-coupled bile acid receptor 1                                                          610147
  GPBAR1       G protein-coupled bile acid receptor 1                                                          610147
  FAM107A      Family with sequence similarity 107, member A (downregulated in renal cell carcinoma 1)         608295
  TU3A         Family with sequence similarity 107, member A (downregulated in renal cell carcinoma 1)         608295
  FAM107A      Family with sequence similarity 107, member A (downregulated in renal cell carcinoma 1)         608295
  DIRC2        Disrupted in renal carcinoma 2                                                                  602773
  RCC4         Disrupted in renal carcinoma 2                                                                  602773
  MNDEC        Microtia with nasolacrimal duct imperforation and eye coloboma                                  611863
  NPC1         Nasopharyngeal carcinoma 1                                                                      607107
  NPCA1        Nasopharyngeal carcinoma 1                                                                      607107
  LOC344967    Acyl-CoA thioesterase 7-like                                                                    611963
  SOAT         Solute carrier family 10 (sodium/bile acid cotransporter family), member 6                      613366
  SLC10A6      Solute carrier family 10 (sodium/bile acid cotransporter family), member 6                      613366
  SLC10A7      Solute carrier family 10 (sodium/bile acid cotransporter family), member 7                      611459
  SSASKS       Solute carrier family 10 (sodium/bile acid cotransporter family), member 7                      611459
  BCC3         Basal cell carcinoma, susceptibility to, 3                                                      613059
  NPCA2        Nasopharyngeal carcinoma, susceptibility to, 2                                                  161550
  BCC6         Basal cell carcinoma, susceptibility to, 6                                                      613063
  AKR1D1       Bile acid synthesis defect, congenital, 2                                                       604741
  SRD5B1       Bile acid synthesis defect, congenital, 2                                                       604741
  CBAS2        Bile acid synthesis defect, congenital, 2                                                       604741
  NCRNA00197   Papillary thyroid carcinoma susceptibility candidate 1 gene                                     617440
  PTCSC1       Papillary thyroid carcinoma susceptibility candidate 1 gene                                     617440
  BCC5         Basal cell carcinoma, susceptibility to, 5                                                      613062
  BAAT         Bile acid coenzyme A: amino acid N-acyltransferase (glycine N-choloyltransferase)               602938
  CEL          Carboxyl-ester lipase (bile-salt stimulated lipase)                                             114840
  BSSL         Carboxyl-ester lipase (bile-salt stimulated lipase)                                             114840
  CELL         Carboxyl-ester lipase (bile-salt stimulated lipase)                                             114840
  MODY8        Carboxyl-ester lipase (bile-salt stimulated lipase)                                             114840
  SART1        Squamous cell carcinoma antigen recognized by T cells 1                                         605941
  HOMS1        Squamous cell carcinoma antigen recognized by T cells 1                                         605941
  ANC          Anal canal carcinoma                                                                            105580
  BCC4         Basal cell carcinoma, susceptibility to, 4                                                      613061
  AQP2         Aquaporin-2 (collecting duct)                                                                   107777
  SART3        Squamous cell carcinoma antigen recognized by T cells 3                                         611684
  P100         Squamous cell carcinoma antigen recognized by T cells 3                                         611684
  KIAA0156     Squamous cell carcinoma antigen recognized by T cells 3                                         611684
  TIP110       Squamous cell carcinoma antigen recognized by T cells 3                                         611684
  SLC10A2      Solute carrier family 10 (sodium/bile acid cotransporter family), member 2                      601295
  NTCP2        Solute carrier family 10 (sodium/bile acid cotransporter family), member 2                      601295
  PBAM         Solute carrier family 10 (sodium/bile acid cotransporter family), member 2                      601295
  SLC10A1      Solute carrier family 10 (sodium/bile acid cotransporter family), member 1                      182396
  NTCP1        Solute carrier family 10 (sodium/bile acid cotransporter family), member 1                      182396
  HDMCP        Hepatocellular carcinoma-downregulated mitochondrial carrier protein                            609911
  C14orf68     Hepatocellular carcinoma-downregulated mitochondrial carrier protein                            609911
  HCCAT5       Hepatocellular carcinoma-associated transcript 5                                                615613
  HTA          Hepatocellular carcinoma-associated transcript 5                                                615613
  MSPC         Palmoplantar carcinoma, multiple self-healing                                                   616964
  ICT1         Immature colon carcinoma transcript 1                                                           603000
  DS1          Immature colon carcinoma transcript 1                                                           603000
  DCC          Deleted in colorectal carcinoma                                                                 120470
  MRMV1        Deleted in colorectal carcinoma                                                                 120470
  HGPPS2       Deleted in colorectal carcinoma                                                                 120470
  SERPINB4     Serpin peptidase inhibitor, clade B (ovalbumin), member 4 (squamous cell carcinoma antigen 2)   600518
  SCCA2        Serpin peptidase inhibitor, clade B (ovalbumin), member 4 (squamous cell carcinoma antigen 2)   600518
  SERPINB3     Serpin peptidase inhibitor, clade B (ovalbumin), member 3 (squamous cell carcinoma antigen 1)   600517
  SCCA1        Serpin peptidase inhibitor, clade B (ovalbumin), member 3 (squamous cell carcinoma antigen 1)   600517
  TCO          Thyroid carcinoma, nonmedullary, with cell oxyphilia                                            603386
  BCAS4        Breast carcinoma amplified sequence 4                                                           607471
  BCAS1        Breast carcinoma amplified sequence                                                             602968
  NABC1        Breast carcinoma amplified sequence                                                             602968
  PICSAR       p38-inhibited cutaneous squamous cell carcinoma-associated long intergenic noncoding RNA        617191
  LINC00162    p38-inhibited cutaneous squamous cell carcinoma-associated long intergenic noncoding RNA        617191
  NLC1C        p38-inhibited cutaneous squamous cell carcinoma-associated long intergenic noncoding RNA        617191
  SLC10A3      Solute carrier family 10 (sodium/bile acid cotransporter family) member 3 (protein p3)          312090
  P3           Solute carrier family 10 (sodium/bile acid cotransporter family) member 3 (protein p3)          312090
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![RA inhibits CCA cell proliferation: (**A**) RA inhibited the viability of QBC939 cells in a dose-dependent manner with CCK8 assay; (**B**) The numbers of QBC939 cells increased slowly after RA treatment. Values represent means±SD, n=5, \* *P*\<0.05, \*\* *P*\<0.01 compared with 0 μg/mL group.](medscimonit-26-e921162-g002){#f2-medscimonit-26-e921162}

![The effect of RA on QBC939 cells detected by trypan blue staining assay. (**A--D**) Represents 0, 100, 200, 400 μg/mL, respectively. (**E**) Shows histogram analysis. Values represent means±SD, n=3, \* *P*\<0.05, \*\* *P*\<0.01, \*\*\* *P*\<0.001 compared with 0 μg/mL group.](medscimonit-26-e921162-g003){#f3-medscimonit-26-e921162}

![Network construction of compound disease targets. (**A**) Venn diagram shows common part between RA with cholangiocarcinoma (CCA). (**B**) Network of RA compound targets and CCA targets. Note: drug compound1 represents (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-\[(2R,5S)-5-propan-2-yloctan-2-yl\]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta\[a\]phenanthren-3-ol); compound2 represents (6aR,11aR)-9,10-dimethoxy-6a,11a-dihydro-6H-benzofurano\[3,2-c\]chromen-3-ol.](medscimonit-26-e921162-g004){#f4-medscimonit-26-e921162}

![PPI network of common targets. (**A**) Nodes mean targets and colors of edges means different relationships. (**B**) Top 30 nodes are likely key proteins in the interaction of cholangiocarcinoma.](medscimonit-26-e921162-g005){#f5-medscimonit-26-e921162}

![GO and pathway analysis. (**A**) GO analysis of common targets of RA and cholangiocarcinoma. The Y-axis represents significant GO biological function processes and the X-axis represents the counts of enriched targets. The gradient of color represents the different adjusted *p* values. (**B**) KEGG analysis for common targets of RA and cholangiocarcinoma. The Y-axis represents significant KEGG pathways and the X-axis represents the ratio of enriched targets in a pathway to all common targets. The size of the nodes shows count of targets, and gradient of color represents the adjusted *p* value.](medscimonit-26-e921162-g006){#f6-medscimonit-26-e921162}

![Correlation of core target expression with immune infiltration level in CCA. (**A**) Caspase3 expression level is significantly negatively related to tumor purity and positively related to the infiltration level of B cells in CCA. (**B**) MYC expression level is significantly negatively related to tumor purity and positively related to the infiltration level of B cells, CD4+ cells, macrophages, neutrophils, and dendritic cells in CCA.](medscimonit-26-e921162-g007){#f7-medscimonit-26-e921162}

![(**A, B**) Changes in core target proteins in QBC939 cells after RA treatment. GADPH was used as loading control. n=3, \* *p*\<0.05 compared with 0 μg/mL group.](medscimonit-26-e921162-g008){#f8-medscimonit-26-e921162}

###### 

Potential active compounds in HMM.

  Molecule ID   Molecule name                                                                                                                                                   OB (%)   DL     Chemical structure
  ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- -------- ------ --------------------
  MOL000211     Mairin                                                                                                                                                          55.38    0.78   
  MOL000239     Jaranol                                                                                                                                                         50.83    0.29   
  MOL000296     Hederagenin                                                                                                                                                     36.91    0.75   
  MOL000033     (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-\[(2R,5S)-5-propan-2-yloctan-2-yl\]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta\[a\]phenanthren-3-ol   36.23    0.78   
  MOL000354     Isorhamnetin                                                                                                                                                    49.6     0.31   
  MOL000371     3,9-di-O-methylnissolin                                                                                                                                         53.74    0.48   
  MOL000378     7-O-methylisomucronulatol                                                                                                                                       74.69    0.3    
  MOL000379     9,10-dimethoxypterocarpan-3-O-β-D-glucoside                                                                                                                     36.74    0.92   
  MOL000380     (6aR,11aR)-9,10-dimethoxy-6a,11a-dihydro-6H-benzofurano\[3,2-c\] chromen-3-ol                                                                                   64.26    0.42   
  MOL000387     Bifendate                                                                                                                                                       31.1     0.67   
  MOL000392     Formononetin                                                                                                                                                    69.67    0.21   
  MOL000417     Calycosin                                                                                                                                                       47.75    0.24   
  MOL000422     Kaempferol                                                                                                                                                      41.88    0.24   
  MOL000433     FA                                                                                                                                                              68.96    0.71   
  MOL000442     1,7-Dihydroxy-3,9-dimethoxy pterocarpene                                                                                                                        39.05    0.48   
  MOL000098     Quercetin                                                                                                                                                       46.43    0.28   

###### 

Common targets between HMM and cholangiocarcinoma.

  Gene ID   Gene symbol   Gene name
  --------- ------------- ----------------------------------------------------
  5241      PGR           Progesterone receptor
  5742      PTGS1         Prostaglandin G/H synthase 1
  1111      CHEK1         Serine/threonine-protein kinase Chk1
  5644      PRSS1         Trypsin-1
  1131      CHRM3         Muscarinic acetylcholine receptor M3
  2099      ESR1          Estrogen receptor
  5468      PPARG         Peroxisome proliferator activated receptor gamma
  2932      GSK3B         Glycogen synthase kinase-3 beta
  2155      F7            Coagulation factor VII
  596       BCL2          Apoptosis regulator Bcl-2
  836       CASP3         Caspase-3
  5599      MAPK8         Mitogen-activated protein kinase 8
  1543      CYP1A1        Cytochrome P450 1A1
  6401      SELE          E-selectin
  240       ALOX5         Arachidonate 5-lipoxygenase
  2950      GSTP1         Glutathione S-transferase P
  196       AHR           Aryl hydrocarbon receptor
  9970      NR1I3         Nuclear receptor subfamily 1 group I member 3
  2944      GSTM1         Glutathione S-transferase Mu 1
  1956      EGFR          Epidermal growth factor receptor
  7422      VEGFA         Vascular endothelial growth factor A
  595       CCND1         G1/S-specific cyclin-D1
  842       CASP9         Caspase-9
  5328      PLAU          Urokinase-type plasminogen activator
  5925      RB1           Retinoblastoma-associated protein
  3569      IL6           Interleukin-6
  8626      TP63          Cellular tumor antigen p53
  2002      ELK1          ETS domain-containing protein Elk-1
  841       CASP8         Caspase-8
  5894      RAF1          RAF proto-oncogene serine/threonine-protein kinase
  5578      PRKCA         Protein kinase C alpha type
  3091      HIF1A         Hypoxia-inducible factor 1-alpha
  2064      ERBB2         Receptor tyrosine-protein kinase erbB-2
  4609      MYC           MYC proto-oncogene protein
  5733      PTGER3        Prostaglandin E2 receptor EP3 subtype
  332       BIRC5         Baculoviral IAP repeat-containing protein 5
  4846      NOS3          Nitric oxide synthase, endothelial
  3315      HSPB1         Heat shock protein beta-1
  891       CCNB1         G2/mitotic-specific cyclin-B1
  4780      NFE2L2        Nuclear factor erythroid 2-related factor 2
  1728      NQO1          NAD(P)H dehydrogenase \[quinone\] 1
  142       PARP1         Poly \[ADP-ribose\] polymerase 1
  11200     CHEK2         Serine/threonine-protein kinase Chk2
  3297      HSF1          Heat shock factor protein 1
  1401      CRP           C-reactive protein
  11186     RASSF1        Ras association domain-containing protein 1
  3659      IRF1          Interferon regulatory factor 1
  2065      ERBB3         Receptor tyrosine-protein kinase erbB-3
  5444      PON1          Serum paraoxonase/arylesterase 1
  3099      HK2           Hexokinase-2
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